Table 2 Summary of Kaplan-Meier analyses of the suitability of expression levels of six genes and pathologic features as predictors of recurrence, metastasis, and survival in patients with bladder cancer (n=251)

	Recurrence-free		Metastasis-free		Overall-survival
	Patients (%)	P-value^*	Patients(%)	P-value^*	Patients (%)	P-value^*
CDH1 ^a (low expression)		0.87		0.01		0.01
Low	8		21		24
High	11		49		48
FN1 ^a (high expression)		0.89		0.2		0.29
Low	4		28		30
High	9		30		31
TOP2A ^a (high expression)		0.1		0.01		0.01
Low	9		45		48
High	7		29		29
CDC2 ^a		0.91		0.3		0.58
Low	7		35		36
High	8		36		39
MMP7 ^a		0.48		0.99		0.95
Low	0		25		27
High	12		41		43
MMP12 ^a		0.12		0.25		0.29
Low	18		42		45
High	3		28		29
Cluster A vs B ^b		0.6		0.1		0.08
Cluster A	19		25		17
Cluster B	11		13		11
CDH1+TOP2A (Cluster D, CDH1 high and TOP2A low)^c		0.1		0.01		0.01
Cluster C	15		39		42
Cluster D	48		81		81
Histologic grade (low (Grade 1–2) vs high (Grade 3))^d		0.97		0.01		0.01
Low grade	6		59		59
High grade	12		20		21
Growth pattern (papillary vs nonpapillary)		0.58		0.01		0.01
Papillary	11		12		13
Nonpapillary	17		52		52
Invasion (superficial (T_a–T_1a) vs invasive (T_1b–T₄))^e		0.64		0.01		0.01
Superficial	8		70		55
Invasive	11		29		15

^*P-values of Kaplan–Meier log-rank test.
^aThe expression for each gene was determined by immunohistochemical analysis in tissue microarray and represents the comparison between the tumor groups expressing low and high level of the gene with the median value of REL differentiating low and high expression levels.
^bClusters A and B were defined on the basis of differential expressions of six genes in tissue microarray as depicted in Figure 6a.
^cUsing immunohistochemical expression levels of CDH1 and TOP2A tumors were classified into two groups—(C) characterized by high expression levels of CDH1 and low expression levels of TOP2A and (D) characterized by overexpression of TOP2A and low expression of CDH1 as shown in Figure 6b.
^dHistologic grading was performed according to WHO grading system for bladder tumors.
^eTumors were staged according to the TNM classification of malignant tumors with T_1a/T_1b substaging.
The feature that correlates with aggressive clinical behavior is shown in parentheses.

Search